News

I write today to announce that Dr. Tatiana Litvin-Vechnyak, currently Associate Vice President for Innovation Ventures at Rutgers University, will serve as Georgetown University’s new Vice President for Technology Commercialization starting February 1, 2023.

Dr. Litvin-Vechnyak brings significant experience and expertise to this critical role, having led the Rutgers Innovation Ventures team’s management of approximately 1,260 technologies, 2,600 patent assets, 800 licenses and 90 startup companies. She holds a Ph.D. in Pharmacology from Cornell University Weill Graduate School of Medical Sciences and a B.A. in Biochemistry and Molecular Biology from Clark University. She has done Postdoctoral Research at Rutgers Cancer Institute of New Jersey where she was a recipient of the Gallo Award for Outstanding Cancer Research. Dr. Litvin-Vechnyak is a Registered Patent Agent; has served on a number of boards over the years, including the Research & Development Council of New Jersey; and was recently elected to the Board of Directors of AUTM -the Association of University Technology Managers.

Catalyze Preclinical Services Program

The Preclinical Services Program expands the support available to innovators with a heart, lung, blood, or sleep to include preclinical development activities from end-stage proof-of-concept through preclinical development and US regulatory submissions. Preclinical services are tailored to the development needs of each product. Applicants can request specific services required to advance their technology to the clinic or regulatory submission. Once a project is selected for support, the level of support and services provided are negotiated between the Principal Investigator and NHLBI.

GAITHERSBURG, MD / ACCESSWIRE / February 23, 2023 / BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“Bullfrog AI” or the “Company”), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a co-development arrangement with the J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation, for the design and validation of a synthetic HSV-1 (herpes simplex type 1) virus particle targeting colorectal cancer.

Exciting News: #AGT CEO, Jeff Galvin, won “the most prestigious leadership award in the life sciences industry” — The Life Sciences Voice Top Industry Leaders Award! It recognizes the industry’s most creative minds working on important initiatives and delivering extraordinary results. Read more. https://bit.ly/3IMfVyC

NCI SBIR is hosting an informational webinarExit Disclaimer on funding and resources designed to assist cancer technology innovators get their projects to the market. This presentation is appropriate for both established small businesses and researchers interested in translating technologies to patients and/or marketplace.  Program Directors Sarra Djemil and William Bozza will cover topics, including:

On Friday, Maryland Gov. Wes Moore and Lt. Gov. Aruna Miller came to North Bethesda to meet with local leaders about a new research facility planned for the area.

“In order for this to be Maryland’s decade, it means it also must be Montgomery County’s decade,” Moore said following a meeting with leaders including County Executive Marc Elrich and county councilmembers. “And this is going to be an important component to actually making that happen.”

Governor Glenn Youngkin has announced the approval of over $66 million in state grants for four projects in the Biotechnology, Life Sciences, and Pharmaceutical Manufacturing Cluster that will help the BioHealth Capital Region continue to flourish as a top national biohub.

These initiatives are aimed at creating job opportunities, raising wages, and promoting economic growth throughout the Commonwealth. Governor Youngkin hopes that by accelerating the growth of the life sciences industry, Virginia will become a leading state in the biotech and pharmaceutical sectors, and improve economic opportunities in what are sometimes considered the BioHealth Capital Region’s “pocket hubs”.

Maryland business dedicated to developing telehealth solutions for remotely monitoring patients with eye and brain diseases

COLUMBIA, Md. (February 16, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent State Small Business Credit Initiative (SSBCI) investment of $150,000 into JuneBrain Inc., an organization focused on creating new ways for physicians to remotely monitor their patients.

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the terms of the definitive agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for the active immunization to prevent typhoid fever, and VAXCHORA®, indicated for the active immunization to prevent cholera, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic will also acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 current Emergent employees are expected to join Bavarian Nordic as part of the transaction.